Related Experiment Videos
Reversal of scopolamine-induced spatial memory deficits in rats by TAK-147
Zhong Chen1, A-Jing Xu, Ren Li
1Department of Pharmacology, School of Medicine, Zhejiang University, Hangzhou 310006, China. chenzfl@hotmail.com
Aim:
To evaluate effect of TAK-147 on spatial memory deficit induced by scopolamine.
Methods:
Morris water maze was used to measure spatial memory in rats and open field test was used to analyse locomotor activity.
Results:
In the acquisition memory process, scopolamine (0.4 mg/kg, ip) markedly increased the escape latency to the platform. Ip injection of both TAK-147 and donepezil ameliorated scopolamine-induced deficit, dose-related and significant effect was obtained at doses of 0.1-1.0 mg/kg. In the memory retrieval process, increased latency induced by scopolamine (1.5 mg/kg, ip) was also significantly reversed by treatment with TAK-147 (0.1, 0.3, and 1.0 mg/kg), donepezil (0.3 and 1.0 mg/kg), and tacrine (3 and 5 mg/kg), respectively. TAK-147 has a little potent efficacy to donepezil, and was more potent than tacrine. In the locomotor test, both TAK-147 and donepizil created no appreciable change of locomotor activities, compared with scopolamine or saline.
Conclusion:
TAK-147 plays an important role in spatial cognition, and this result provides additional evidence that TAK-147 is an ideal AChE inhibitor and is useful for the treatment of Alzheimer's disease.
Insights
TAK-147 effectively reverses scopolamine-induced spatial memory deficits in rats. This acetylcholinesterase inhibitor shows promise for treating Alzheimer's disease by improving cognitive function without affecting locomotor activity.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Scopolamine administration induces spatial memory deficits in rodents, serving as a model for cognitive impairment.
- Alzheimer's disease is characterized by progressive memory loss and cognitive decline, necessitating the development of effective treatments.
Purpose of the Study:
- To investigate the efficacy of TAK-147, a novel acetylcholinesterase (AChE) inhibitor, in ameliorating scopolamine-induced spatial memory impairment in rats.
- To compare the therapeutic potential of TAK-147 with established AChE inhibitors like donepezil and tacrine.
Main Methods:
- Spatial memory was assessed using the Morris water maze test in rats.
- Locomotor activity was evaluated through an open field test to rule out confounding motor effects.
- Scopolamine was used to induce memory deficits, and TAK-147, donepezil, and tacrine were administered at various doses.
Main Results:
- TAK-147 significantly reduced the escape latency in the Morris water maze, indicating improved spatial memory acquisition and retrieval.
- The therapeutic effects of TAK-147 were dose-dependent, with significant improvements observed at doses ranging from 0.1 to 1.0 mg/kg.
- TAK-147 demonstrated potent AChE inhibitory activity, comparable to donepezil and superior to tacrine, without inducing significant changes in locomotor activity.
Conclusions:
- TAK-147 effectively mitigates scopolamine-induced spatial memory deficits, highlighting its role in enhancing spatial cognition.
- These findings support TAK-147 as a promising acetylcholinesterase inhibitor for the potential treatment of Alzheimer's disease.
- TAK-147's efficacy and safety profile suggest its utility in managing cognitive impairments associated with neurodegenerative conditions.